Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe’s MRI sector waits on directive rethink

This article was originally published in Clinica

Executive Summary

Of all the ill-conceived and backward-thinking EU directives, the Physical Agents Directive (Directive 2004/40/EC), also known as the EMF Directive, is up there among the worst. The directive is potentially disastrous for the MRI sector as it seeks to impose strict limits on the electromagnetic field (EMF) strengths to which equipment operators can legally be exposed. While moves to protect workers from over-exposure to EMFs are to be welcomed, the directive is so restrictive that it could prevent healthcare staff caring for patients during a scan, put an end to interventional MRI procedures, and prevent radiologists from being properly trained. It could also affect MRI research, leading to a brain drain from the EU to the US and Asia.

You may also be interested in...

Google/DeepMind Tech Could ‘Transform Double-Reading In Mammography’

An algorithm has been shown to be as effective as radiologists in spotting breast cancer from mammograms, backing previous predictions that machine learning will find increasing use as a "second reader" in screening programs.

RSNA 2019: AI, Machine Learning Continue To Dominate Developments In Radiology

Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.

AHA 2019: Cardiawave Sees Positive Early Results For Non-Invasive Valve Disease Treatment

The French start-up claims first-in-man success for heart valve “softening” treatment and plans further trials for an EU launch.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts